Express News | MaxCyte, Inc. MaxCyte, Inc. - Mxcr - Filing of Definitive Proxy Statement
BlackRock Adjusts Stake in MaxCyte, Inc.
MaxCyte Announces Change in Major Shareholder Holdings
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating
MaxCyte to Propose AIM Delisting to Shareholders
Express News | MaxCyte Inc - Proposes Cancellation of Aim Listing, Continues Nasdaq Listing
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
With 66% Institutional Ownership, MaxCyte, Inc. (LON:MXCT) Is a Favorite Amongst the Big Guns
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know
MaxCyte Expands Capital With New Stock Issuance
MaxCyte Announces CFO's RSU Vesting and Share Sale
MaxCyte Announces Change in Major Shareholder Voting Rights
MaxCyte Awards Stock Options and Units to Executives
Insider Sale: CHIEF FINANCIAL OFFICER of $MXCT Sells 6,939 Shares
MaxCyte Management to Meet With BTIG
BlackRock Increases Stake in MaxCyte to 7.71%
BTIG Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $6
BTIG Reaffirms Their Buy Rating on MaxCyte (MXCT)
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup